Log In
BCIQ
Print this Print this
 

AVP-786, CTP-786 (formerly deuterated dextromethorphan)

  Manage Alerts
Collapse Summary General Information
Company Concert Pharmaceuticals Inc.
DescriptionDeuterium-modified dextromethorphan -- an NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of serotonin and norepinephrine transporters -- plus ultra-low-dose quinidine, a cytochrome P450 2D6 (CYP2D6) inhibitor
Molecular Target NMDA receptor ; Sigma-1 receptor
Mechanism of ActionNMDA receptor antagonist; Sigma-1 receptor agonist; Cytochrome P450 2D6 (CYP2D6) inhibitor; Serotonin transporter (SERT) inhibitor; Norepinephrine transporter (NET) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$200.0M

0

$200.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/05/2012

$200.0M

Undisclosed

$200.0M

Get a free BioCentury trial today